Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 80

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 80
---
otment option was exercised in full by the underwriters and these shares are no longer subject to forfeiture.

Rights — Except
in cases where the Company is not the surviving company in a Business Combination, each holder of a right will automatically receive
one-eighth (1/8) of one ordinary share upon consummation of the initial Business Combination. The Company will not issue fractional shares
in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed
in accordance with the applicable provisions of Cayman law. In the event the Company is not the surviving company upon completion of
the initial Business Combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to
receive the one-eighth (1/8) of one ordinary share underlying each right upon consummation of the Business Combination. If the Company
is unable to complete the initial Business Combination within the required time period and the Company will redeem the public shares
for the funds held in the Trust Account, holders of rights will not receive any of such funds for their rights and the rights will expire
worthless.

15

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Representative
Shares — The Company issued to Clear Street LLC, the representative of the underwriters in the Initial Public Offering,
200,000 ordinary shares (the “representative shares”) at the time of the consummation of Initial Public Offering and 30,000
representative shares at the closing of the over-allotment option. The holders of the representative shares have agreed (i) that they
will not transfer, assign or sell any such shares without our prior consent until the completion of the initial Business Combination,
(ii) to waive their redemption rights (or right to participate in any tender offer) with respect to such shares in connection with the
completion of the initial Business Combination and (iii) to waive their rights to liquidating distributions from the Trust Account with
respect to such shares if the Company fails to complete its initial Business Combination within 15 months from the closing of the Initial
Public Offering (or up to 21 months from the closing if the Company extends the period of time to consummate a Business Combination).

The
representative shares have been deemed compensation by FINRA and are therefore subject to a lock-up